Entera Bio Ltd. (ENTX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing first-in-class oral tablet formats of peptides or protein replacement therapies. The company's primary focus is on underserved chronic conditions, specifically osteoporosis (EB613) and hypoparathyroidism (EB612), utilizing its proprietary N-Tab™ oral delivery technology. The company is incorporated in Israel and listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $57,000 | $57,000 | $0 |
| Net Loss | $(2,145,000) | $(4,162,000) | $(4,515,000) |
| Operating Loss | $(2,165,000) | $(4,227,000) | $(4,542,000) |
| Cash and Cash Equivalents | $9,056,000 (as of June 30, 2024) | Balance Sheet Item | |
| Accumulated Deficit | $(108,548,000) | Balance Sheet Item | |
| Net Cash Used in Operating Activities | $(3,197,000) | $(3,197,000) | $(3,168,000) |
| Net Cash Provided by Financing Activities | $1,246,000 | $1,246,000 | $5,000 |
Note: Revenue recognized in Q2 2024 is derived from a research services agreement entered into in April 2024. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $57,000 in revenue for the first time in the current quarter, compared to zero in the prior year period, attributable to a new research services agreement.
- Expense Reduction: Research and Development (R&D) expenses decreased by 15% year-over-year for the six-month period ($1.82M vs. $2.14M), primarily due to reduced clinical expenses for Phase 1 PK studies and lower consultant costs.
- Financing Activity: Net cash provided by financing activities increased significantly to $1.25M for the six months ended June 30, 2024, compared to $5,000 in the prior year. This was driven by $601,000 in proceeds from the At-The-Market (ATM) program and $645,000 from the exercise of options and warrants.
- Cash Position: Cash and cash equivalents decreased by approximately $1.95M during the six-month period, leaving the company with $9.1M as of June 30, 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt regarding the company's ability to continue as a going concern. While current cash resources are projected to fund operations into the third quarter of 2025, the company lacks sufficient capital to fund the proposed Phase 3 study for EB613 without additional financing.
- Capital Needs: The company will need to raise additional capital through equity offerings, debt financing, or strategic collaborations to advance its clinical programs, specifically the Phase 3 registrational study for EB613.
- Geopolitical Risks: The filing highlights significant risks related to the ongoing war in Israel (Hamas conflict) and regional instability involving Iran and its proxies. While operations have not been materially impacted to date, the company notes potential risks to its workforce, supply chain, and ability to raise capital due to the downgraded credit rating of Israel.
- Clinical Progress: The company is preparing to initiate a Phase 3 study for EB613 pending FDA qualification of a quantitative BMD endpoint. Collaboration with OPKO Biologics on oral GLP-2 and OXM programs continues with expected data in 2024.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the sufficiency of the $9.1M cash balance to reach the third quarter of 2025 without dilution.
- Phase 3 Funding: Confirm the estimated cost to launch the EB613 Phase 3 study and the status of discussions with the FDA regarding the BMD endpoint qualification.
- Financing Strategy: Assess the availability of the remaining capacity under the Leerink ATM program and the likelihood of securing private or public equity financing in the current market environment.
- Geopolitical Exposure: Evaluate the potential impact of the Israel-Hamas conflict and regional instability on the company's ability to retain key personnel and maintain its supply chain.
- Revenue Sustainability: Determine the duration and total value of the research services agreement that generated the $57,000 in revenue.